07:00 , Apr 8, 2013 |  BC Week In Review  |  Company News

AlphaCore, AstraZeneca deal

AstraZeneca's MedImmune LLC biologics unit acquired cardiovascular company AlphaCore. The companies declined to provide details. AlphaCore is developing ACP-501, a recombinant human lecithin-cholesterol acyltransferase (LCAT), for atherosclerosis and familial LCAT deficiency. The...
07:00 , Apr 8, 2013 |  BioCentury  |  Strategy

AstraZeneca's reset

After spending at least $7 billion for late-stage assets in 2012, AstraZeneca plc believes it now has sufficient value in its Phase II/III pipeline to restore long-term growth. The attention of business development is now...
23:32 , Apr 3, 2013 |  BC Extra  |  Top Story

MedImmune acquires CV company AlphaCore

The MedImmune LLC biologics unit of AstraZeneca plc (LSE:AZN; NYSE:AZN) acquired cardiovascular company AlphaCore Pharma (Ann Arbor, Mich.). Details of the deal were not disclosed. AlphaCore is developing ACP-501, a recombinant human lecithin-cholesterol acyltransferase (LCAT),...
08:00 , Dec 10, 2012 |  BC Week In Review  |  Company News

AlphaCore Pharma LLC, Axerion Therapeutics, Optimum Therapeutics LLC, NIH cancer, cardiovascular, neurology news

NIH selected three projects for 2012 to receive no-cost access to NIH development contractor resources under its Bridging Interventional Development Gaps (BrIDGs) program. The program aims to help projects from academic institutions, not-for-profits and Small...
02:16 , Dec 5, 2012 |  BC Extra  |  Politics & Policy

NIH selects three more projects for BrIDGs program

NIH selected three projects for 2012 to receive no-cost access to NIH development contractor resources under its Bridging Interventional Development Gaps (BrIDGs) program. The program aims to help projects from academic institutions, not-for-profits and SBIR/STTR-eligible...
08:00 , Nov 19, 2012 |  BC Week In Review  |  Clinical News

ACP-501 regulatory update

The European Commission granted Orphan Drug designation to AlphaCore's ACP-501 to treat familial lecithin-cholesterol acyltransferase (LCAT) deficiency, a rare, inherited disease that causes lipid accumulation in the eyes, red blood cells and kidneys. The...
07:00 , Oct 22, 2012 |  BC Week In Review  |  Clinical News

ACP-501: Phase I data

An open-label, U.S. Phase I trial in 16 patients with stable atherosclerosis showed that single ascending-doses of IV ACP-501 were well tolerated. AlphaCore also said ACP-501 met the secondary endpoint of elevating HDL-C, but declined...
07:00 , Apr 9, 2012 |  BC Week In Review  |  Clinical News

ACP-501: Phase I started

AlphaCore said NIH began an open-label, single dose-escalating Phase I trial to evaluate 3 doses of IV ACP-501 in 18 patients with stable CAD. AlphaCore Pharma, Ann Arbor, Mich.   Product: ACP-501   Business: Cardiovascular   Molecular...